Annovis Bio, Inc. (ANVS) income statement
ANVSNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.71−0.04 (-4.96%)
Close on Nov 20, 2026Market cap $30.31MP/E –Yield –
Annovis Bio, Inc. financial ratios
See a number that looks wrong?
Close on Nov 20, 2026Market cap $30.31MP/E –Yield –
See a number that looks wrong?
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Returns on capital | ||||||||
| Return on equity | -220.6% | -3,624.9% | -546.4% | -69.6% | -55.7% | 1,055.0% | 12.3% | – |
| Return on assets | -164.8% | -203.8% | -243.1% | -61.8% | -53.5% | -118.3% | -88.7% | – |
| Return on tangible assets | -164.8% | -203.8% | -243.1% | -61.8% | -53.5% | -118.3% | -88.7% | – |
| Return on capital employed | -216.0% | -334.2% | -263.0% | -70.1% | -55.9% | -199.8% | 179.7% | – |
| NOPAT | -$23.46M | -$21.09M | -$35.58M | -$20.15M | -$11.48M | -$5.25M | -$1.27M | – |
| Cash flow quality | ||||||||
| OCF / Net income | 0.89 | 0.89 | 0.71 | 0.68 | 0.63 | 0.73 | 0.48 | – |
| Efficiency | ||||||||
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | – |
| Liquidity | ||||||||
| Current ratio | – | – | 2.39 | 4.68 | 30.54 | 14.04 | 0.37 | – |
| Quick ratio | – | – | 2.39 | 4.68 | 30.54 | 14.04 | 0.37 | – |
| Cash ratio | 5.37 | 2.72 | 1.34 | 3.69 | 30.33 | 13.96 | 0.00 | – |
| Working capital | – | – | $5.93M | $28.32M | $44.49M | $7.54M | -$1.26M | – |
| Net current asset value | – | – | -$7.75M | $28.32M | $44.49M | $7.54M | -$1.87M | – |
| Leverage | ||||||||
| Assets to equity | 1.25 | 1.50 | -1.32 | 1.27 | 1.03 | 1.08 | -0.13 | – |
| Per share | ||||||||
| Revenue per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | – |
| EPS (basic) | -1.40 | -2.02 | -6.23 | -3.10 | -1.90 | -0.87 | -3.51 | – |
| EPS (diluted) | -1.40 | -2.31 | -6.23 | -3.10 | -1.90 | -0.87 | -3.51 | – |
| Book value per share | 0.62 | 0.66 | -0.74 | 3.47 | 5.49 | 1.09 | -30.35 | – |
| Tangible book value per share | 0.62 | 0.66 | -0.74 | 3.47 | 5.49 | 1.09 | -30.35 | – |
| Cash per share | 0.72 | 0.75 | 0.55 | 3.48 | 5.64 | 1.17 | 0.0066 | – |
| Operating cash flow per share | -0.94 | -1.55 | -3.80 | -2.12 | -1.13 | -0.58 | -1.69 | – |
| Valuation at period end | ||||||||
| Market cap | $69.85M | $66.82M | $168.53M | $109.64M | $142.41M | $51.81M | – | – |
| Enterprise value | $54.56M | $54.18M | $162.17M | $77.65M | $94.95M | $42.97M | – | – |
| P/B | 4.1x | 7.2x | -21.7x | 3.9x | 3.2x | 6.9x | – | – |
| P/TBV | 4.1x | 7.2x | -21.7x | 3.9x | 3.2x | 6.9x | – | – |
| P/OCF | -2.7x | -3.1x | -4.2x | -6.3x | -15.6x | -13.0x | – | – |
| EV/OCF | -2.1x | -2.5x | -4.1x | -4.5x | -10.4x | -10.8x | – | – |
| Earnings yield | -41.3% | -36.8% | -33.3% | -23.1% | -10.2% | -10.5% | – | – |
| Per employee | ||||||||
| Total employees | 8 | 8 | 6 | 5 | 2 | 2 | 2 | 2 |
| Revenue per employee | $0 | $0 | $0 | $0 | $0 | $0 | $0 | – |
| Operating profit per employee | -$3.71M | -$3.34M | -$7.51M | -$5.10M | -$7.27M | -$3.32M | -$802.81K | – |
| Net income per employee | -$3.61M | -$3.07M | -$9.37M | -$5.07M | -$7.24M | -$2.73M | -$495.49K | – |
| Growth | ||||||||
| EBIT 1Y growth | -11.2% | 40.7% | -76.5% | -75.5% | -118.9% | -313.6% | – | – |
| Net income 1Y growth | -17.3% | 56.2% | -121.9% | -74.8% | -165.2% | -451.2% | – | – |
| Diluted EPS 1Y growth | 39.4% | 62.9% | -101.0% | -63.2% | -118.4% | 75.2% | – | – |
| Operating cash flow 1Y growth | -17.0% | 45.2% | -130.9% | -89.6% | -130.0% | -733.3% | – | – |
| Total assets 1Y growth | 51.4% | 36.4% | -71.7% | -21.7% | 466.6% | 626.8% | – | – |
| Total assets 3Y CAGR | -16.4% | -32.9% | 7.9% | 218.3% | – | – | – | – |
| Total assets 5Y CAGR | 21.0% | 65.6% | – | – | – | – | – | – |
| Total equity 1Y growth | 81.0% | 220.1% | -127.4% | -36.3% | 490.0% | 187.9% | -12.9% | – |
| Total equity 3Y CAGR | -15.9% | -40.6% | – | – | – | – | – | – |
| Total equity 5Y CAGR | 17.4% | – | – | – | – | – | – | – |
Every figure here is calculated from standardized financial statements — hover a row name for the formula — not reported by the company. Valuation multiples use the closing price at the end of that period, not today's price.